Back to Search
Start Over
New Systemic Treatment Options for Hepatobiliary Cancers
- Source :
- Journal of the National Comprehensive Cancer Network. 19:633-635
- Publication Year :
- 2021
- Publisher :
- Harborside Press, LLC, 2021.
-
Abstract
- Multiple systemic therapy options now exist for unresectable and metastatic hepatocellular carcinoma (HCC). Atezolizumab + bevacizumab is the preferred first-line regimen, and although many second-line treatment options have recently been added to the NCCN Guidelines, none have been studied after atezolizumab + bevacizumab (all post-sorafenib), and therefore optimal sequence has yet to be established. Multiple new combination regimens with immune checkpoint inhibitors are also being studied in advanced-stage HCC. In biliary tract cancer (BTC), gemcitabine + cisplatin remains the preferred first-line regimen. FOLFOX is the preferred regimen in the second line. Multiple targeted therapy options are now available in second-line BTC for patients with tumors harboring specific mutations, and these therapeutic targets may guide future treatment sequence and combinations for BTCs.
Details
- ISSN :
- 15401413 and 15401405
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- Journal of the National Comprehensive Cancer Network
- Accession number :
- edsair.doi...........51d9012b6a17df41f71d00d6082833ef